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Background: DNA methylation is a crucial epigenetic modification of the genome which is involved in embryonic
development, transcription, chromatin structure, X chromosome inactivation, genomic imprinting and chromosome
stability. Consistent with these important roles, DNA methylation has been demonstrated to be required for
vertebrate early embryogenesis and essential for regulating temporal and spatial expression of genes controlling
cell fate and differentiation. Further studies have shown that abnormal DNA methylation is associated with human
diseases including the embryonic development diseases. We attempt to study the DNA methylation status of CpG
islands in fetus related to fetus growth and development.
Methods: GeneChip® Human Tiling 2.0R Array set is used for analysis of methylated DNA in a whole-genome wide
in 8 pairs amniotic fluid and maternal blood DNA samples.
Results: We found 1 fetus hypermethylation DNA markers and 4 fetus hypomethylation DNA markers though a
Genome-wide analysis. These DNA markers all found to be associated with the critical genes for fetus growth and
development (SH2D3C gene, EML3 gene, TRIM71 gene, HOXA3 gene and HOXA5 gene).
Conclusions: These genes can be used as a biomarker for association studying of embryonic development,
pathological pregnancy and so on. The present study has provided new and fundamental insights into the roles
that DNA methylation has in embryonic development and in the pathological pregnancy.
Keywords: DNA methylation, Fetus, GeneChip® human tiling 2.0R array set, Clone sequencing, Embryonic
developmentBackground
DNA methylation, the most important and common
part of epigenetic, regulates gene expression by modified
DNA without the changing of the genomic sequence.
DNA methylation is a process in which a methyl group
is covalently bound to a 5-position of cytosine in the
context of a cytosine-guanine dinucleotide (CpG) in the
mammalian genome [1]. Methylation of CpG-rich pro-
moters is used by mammals to prevent transcriptional
initiation, to ensure the inactivation of X chromosome
and the silence of imprinted genes and parasitic DNAs.* Correspondence: syyliaoshixiu@163.com; zhubofeng7372@126.com
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unless otherwise stated.Recent studies show that methylation also affects the
stability and structure of chromosomes. And the abnor-
mal hypomethylation can cause many human diseases
including many kinds of cancer [2,3]. However, the po-
tential roles of methylation in tissue-specific gene ex-
pression and in the regulation of CpG-poor promoters
are less well established [4]. On the other hand, Xiang H
et al. estimate that more than 0.11% of genomic cyto-
sines are methylcytosines, all of which probably occur in
CG dinucleotides. CG methylation is substantially enriched
in gene bodies and positively correlated with gene expres-
sion levels, suggesting it has a positive role in gene tran-
scription [5].
Recently, researchers have conducted extensive re-
search on the mechanism of DNA methylation and its
role in embryonic development. DNA methylation has
been demonstrated to be required for vertebrate earlytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,









p356 28 G1P0 18 week 46,XX
p357 37 G2P0 19 week + 3 day 46,XX
p358 33 G1P0 20 week 46,XX
p359 24 G3P0 19 week + 6 day 46,XY
p360 32 G4P1 22 week 46,XY
p362 27 G1P0 21 week + 5 day 46,XX
p363 38 G3P1 20 week + 5 day 46,XX
p364 30 G2P1 24 week + 2 day 46,XX
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pression of genes controlling cell fate and differentiation
which is a complicated and predetermined developmen-
tal program. Moreover, DNA methylation provides ne-
cessary direction for the multitude of changes that are
required to proceed from a fertilized oocyte to a fully de-
veloped adult animal [6,7]. Sperm and eggs carry dis-
tinctive epigenetic modifications that are adjusted by
reprogramming after fertilization. The paternal genome
in a zygote undergoes active DNA demethylation before
the first mitosis [8]. During the early phases of mamma-
lian development, DNA methylation is extensively repro-
grammed [9]. The maintenance of DNA methylation
and normal methylation level is necessary for normal
embryonic development and tissue-specific differenti-
ation. The changes of DNA methylation will result in
abnormal expression of gene and produce various phe-
notypes such as pregnancy failure, congenital defects
and acquired diseases. For the design of targeted therap-
ies to abnormal DNA methylation, there is important
theoretical and clinical significance to studying and un-
derstanding the status of DNA methylation in the devel-
opment of embryo.
Methylated Microarray analysis is efficient technology
platform for looking for epigenetic methylation markers.
With the completion of many whole-genome sequences,
new types of genome-wide experiments are possible. Til-
ing Arrays offer a physical readout of a genome and can
be used as a discovery tool for mapping sites of DNA
interaction in chromatin immunoprecipitation (ChIP)
experiments, understanding global epigenomic changes
like methylation. Currently, most studies use various
animal models to study the methylation status during
embryonic development. In this study, GeneChip® Hu-
man Tiling 2.0R Array set is used to look for methyla-
tion markers in amniotic fluid samples in an early
development of human embryo. Moreover, clone se-
quencing is used to test and verify the results of Methyl-
ated Microarray analysis. And Real-time quantitative
PCR (RTQ-PCR) is used to verify the function of hyper-




Eight women with 18–24 weeks of euploid pregnancies
admitted to Prenatal Diagnosis Center of Henan Provin-
cial People’ hospital between March 2013 and May 2013
were recruited. 10 ml maternal peripheral blood and
20 ml amniotic fluid were collected from the 8 partici-
pants. All samples were frozen at −80°C before analysis.
The pregnant information about the participants was
shown in Table 1. All the participants were not compli-
cated with any diseases and provided their writteninformed consent for the collection of the samples and
subsequent analysis. The investigation was conducted in
accordance with humane and ethical research principles
of Henan Provincial People’ hospital, China. This study
was approved by the Ethics Committee of Henan Pro-
vincial People’s Hospital, China.
Exclusion of maternal DNA
The fifteen autosomal STR loci and a Amelogenin locus
are amplified to determine whether there is maternal
DNA in fetus amniotic fluid by using the PowerPlex® 16
system kit in a multiplex amplification reaction system
following manufacturer’s instructions using 25 μl reactions
containing 1.0 μl (0.5-2 ng) genomic DNA, 5.0 μl Power-
Plex® 16 5 ×Master Mix, 5.0 μl PowerPlex® 16 5 × Primer
Pair Mix and 14.0 μl ddH2O. Thermal cycling was per-
formed using the GeneAmp® PCR System 9700 (Applied
Biosystems, Foster City, CA, USA). Temperature cycling
conditions for PCR reactions are as follows: denaturation
for 11 min at 95°C, and then 1 min at 96°C, followed by
10 cycles for 30 s at 94°C, 30 s at 60°C, 45 s at 70°C, then
20 cycles for 30 s at 90°C, 30 s at 60°C, 45 s at 70°C and a
final elongation step at 60°C for 30 min.
The PCR products have been separated and detected
by capillary electrophoresis on an ABI 3130 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
2 μl PCR product or Allelic Ladder has been mixed with
15 μl Hi-Di formamide and 0.5 μL internal lane standard
ILS 600 (Promega, WI, USA). The loading mixture has
been denatured at 95°C for 3 min, followed by chilling
on ice for 3 min immediately. STR alleles have been ana-
lyzed by comparison with kit allelic ladders using the
GeneMapper ID 3.2 software (Applied Biosystems,
Foster City, CA, USA). Control DNA from cell line 9947A
(Promega, Madison, WI, USA) has been genotyped as
standard reference in all experiments.
Methylated DNA capture
Methylamp™ Methylated DNA Capture kit (Epigentek
Group Incorporation, Farmingdale, New York, USA) has
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ments from blood and amniotic fluid samples for use in
gene-specific DNA methylation studies on a genome
wide scale. According to the manufacturer’s protocol of
the kit, Methylated DNA Capture include the following
steps: i) DNA isolation, ii) breaking DNA as fragments
by sonicator: sonication for 10 s, and pause 30 s, repeat it
15 times at 100 W, check the DNA size by running 1.2%
agarose gel, iii) incubating sonicated/digested DNA at
98°C for 3 min and immediately put on ice, iv) bisulfite
conversion and methylated DNA immunoprecipitation, v)
release of mDNA from antibody complex, vi) capturing of
mDNA, vii) elution of mDNA. Following methylated
DNA immunoprecipitation (meDIP) processed, the meth-
lation of the DNA can be analyzed using meDIP-ChIP.
DNA methylation analysis
GeneChip® Human Tiling 2.0R Array set (Affymetrix In-
corporation, Santa Clara, CA, USA) has been used for
analysis of methylated DNA in a whole-genome wide.
GeneChip® Fluidics Station 400 and GeneChip® Scanner
3000 7G (Affymetrix Incorporation, Santa Clara, CA,
USA) are needed for analysis. According to the Affyme-
trix chip-on-chip procedures we first amplified immuno-
precipitated DNA targets using the following cycle
conditions: 14 cycles for 30 s at 95°C, 30 s at 45°C, 30 s
at 55°C, 1 min at 72°C, then 14 cycles for 30 s at 95°C,
30 s at 45°C, 30 s at 55°C (for every subsequent cycle
add 5 second), 1 min at 72°C, and 4°C for ever. Sec-
ondly, we purified the PCR products using MiniElute
PCR purification kit (Qiagen Incorporation, Valencia,
CA, Spain) and got fragmentation mix, then put up frag-
mentation mix for Tiling array, following this step we
used GeneChip® WT Double-Stranded DNA Terminal
Labeling Kit (Affymetrix Incorporation, Santa Clara, CA,
USA) to label fragmented Double-Stranded DNA, and
used GeneChip® Hybridization, Wash, and Stain Kit
(Affymetrix Incorporation, Santa Clara, CA, USA) to
hybridize, wash and stain the labeled target DNA ac-
cording to the procedure of the kit. Finally, we scan the
barcode on the chip using appropriate protocol.
Clone sequencing
Clone sequencing strategy has been used to verify the
selected methylation markers by microarray analysis
method in a whole-genome wide (Sangon Biotech In-
corporation, Shanghai, China). Before the clone sequen-
cing was conducted, bisulfite conversion of the sample
genomic DNA was done by using EpiTect Bisulfite kit
(Qiagen Incorporation, Valencia, CA, Spain) according
to the manufacturer’s procedure. Nine fetus hyper-
methylation markers and twelve fetus hypomethylation
markers were tested. The primer sequences were shown
in Table 2.Real-time quantitative PCR
Real-time quantitative PCR was used to verify the func-
tion of hypermethylation and hypomethylation in the
identified genomic regions. Total RNA was prepared
from maternal peripheral blood and amniotic fluid sam-
ples (400 mg) using TRIzol® Reagent (Life Technologies
Incorporation, CA, USA). Reverse transcription was car-
ried out with the GeneAmp® PCR System 9700 (Applied
Biosystems, Foster City, CA, USA) in a reaction volume
of 20 μl containing 5 μl of total RNA, 1 μl random
Primers, 5 μl Rnase-free ddH2O, 4 μl Reaction Buffer 5×,
2 μL dNTP Mix(10 mmol/L), 20U ribonuclease inhibitor
(Applied Biosystems, Foster City, CA, USA), and 20 U of
reverse transcriptase (Life Technologies Incorporation,
Ambion. CA, USA). Specific primers used to amplify
the genes ERG, SH2D3C, EML3, TRIM71, HOXA3,
HOXA11, and HOXA5 (showed in Table 3) were designed
using online software Primer 3 Version 0.4.0 (Whitehead
Institute, USA), and the endogenous β-actin was em-
ployed as an internal standard. Sybr Green RTQ-PCR ana-
lysis were performed with LightCycler480 Software Setup
(Roche Incorporation, Basel, Switzerland). RTQ-PCR was
performed using the following cycle parameters: 3 minutes
at 95°C, followed by 40 cycles of 15 sec at 95°C and 40s at
60°C. For each gene, RTQ-PCR was conducted in 20 μl re-
actions of 1 μl cDNA (5 ng), 10 μl Sybr Green qPCR Mas-
ter Mix 2× (Applied Biosystems, Foster City, CA, USA),
1 μl of each primer (10 μM), 7 μl ddH2O. To ensure the
quality of the measurements, both negative and positive
controls were systematically included in duplicate in each
plate.
Statistical analysis
Affymetrix® Tiling Analysis Software (TAS) was used for
analysis and quality control of the GeneChip Tiling Arrays.
TAS analyzed feature intensity data stored in GeneChip®
Operating Software (GCOS), output cel files and produced
signals and p-values for each genomic position interro-
gated. Affymetrix Power Tools Software 1.15.1 was used
to convert cel files to text files. The methylation regions of
fetus group and mother control group were compared by
using Modle-based Analysis of Tiling-array (MAT) calcu-
lation (p < 0.0001). CisGenome ver 2.0 Software (http://
www.biostat.jhsph.edu/~hji/cisgenome/) was used for an-
notating the gene names which were close to methylation
regions. Scatter plots were constructed utilizing R Soft-
ware Packages 3.0.1. Two sets of results (the fetus and the
mohter) of clone sequencing were analyzed by Quantifica-
tion tool for Methylation Analysis (QUMA) and compared
by statistical software SPSS Version 13.0 using Analysis of
Variance (ANOVA) method (p < 0.01). The statistical ana-
lysis of the RTQ-PCR results was done using ΔΔCt
methods. Analysis of Variance (ANOVA) was also used for
comparison the two sets of results of RTQ-PCR (p < 0.01).
Table 2 The primers for clone sequencing
Primer name Forward primer Reverse primer Amplicon size (bp)
FH1 GGAGTTTTTTATGTATTTGGTATTT CATACCCCCAAAAAATAAAATTTAAAATCT 383
FH2 ATGGGGAAGTAGATTTGGGTAT TCACTTTAACTACCCCCAAATATTATAA 456
FH3 TAGGGGTGTTATGAAGGTGGTA ATTCTATATAATCACTTCCACATTCTTAAT 418
FH4 AGGGTTGGGTAATATTTTTATTGTTATAAT ACAAACCAAATTACCCCCATT 492
FH5 ATGGGAGGTGGGTTTTGTT AAAATCACCTACCAACCTCAATAACTA 446
FH6 GGTTTTTTAGATTTGGATGTGATTTAGG CCCCCCCATAAATAAAACCTT 470
FH7 GTGGAGATAGTAGTGAGTAGAGA AATCCCATATAAACCCAAACCT 484
FH8 TTTTTTTTGTAGTTTAGGGTTTTTTGTAT CTCTTCTAAAACATCCACCTTACA 391
FH9 TGAGAAATTTAAGGAGTGTGTGT TACCCCCATCTATCCTATACTCT 452
FL1 GGGAGGAAGGAGTTGGTAGGTTTTTAT ACTACCCAAATCTCTCACTTTACAATAAC 357
FL2 GTTTTTAGTTAAGTTTTTTGGGGAGAGG AACAACTAATTTCACACCATATCTTAT 349
FL3 TGGGAAGTATGTGGAAGTGGA CACCCCCCATTTTAAAAACAACAATCTAT 290
FL4 GGAAATGTGTTAAGGTAAGAGGTTATAAG CCAAAACTTCTACCCCTAAAAAT 452
FL5 TTTTGTTAAGAATAATAAGAGAGGGTAAGT ATCTATAAATCTTTTTTCCAAACTCAC 481
FL6 GGGTTTTTTGTTTAATTGTGTATTGGAG ACCTAACCAAACCCCATACT 388
FL7 GGATTATTAGTTGTATAATTATGGAGATT ACCCCCTCTCTACTACTAATATAA 378
FL8 AAGGGGATTTTTTTGGAAAGTAT CATCTCAAACTCTCACCATCATAAATA 489
FL9 GTGTTTAGTAATAGGTAGTTTGGAAAATT CTTACTTACAATTCCAATACCTATAATCAC 435
FL10 TGGTATTAGTGGGAGTTTAATAGATG AACTCAAATAAACCCACATACACTATAAT 413
FL11 TGGATTGATATAGGGAAAAAAAAGGAGAA CACTCCCAAATCTCTACTAACCTCTA 465
FL12 GTGGGTTTTATTTAGGTTGTGAGTA CTTAAACTCCTCTTCCCCAACAC 350
FH indicates fetus hypermethylation DNA markers and FL indicates fetus hypomethylation DNA markers.
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DNA Methylation is a crucial epigenetic modification
involved in embryonic development, transcription, chro-
mation structure, X chromosome inactivation, gene
imprinting, chromosome stability and occurrence of dif-
ferent kinds of tumors [10-15]. In recent years, re-
searchers have conducted extensive studies on the
mechanism of DNA methylation and its role in embry-
onic development using different biological models, such
as human and mouse cell lines, gene knockout mice,
zebra fish and so on [6,7,16-18]. These studies all show
that DNA methylation is important for regulating tem-
poral and spatial expression of genes for controlling cellTable 3 The primers for real-time quantitative PCR







HOXA5 GCGAGCCACAAATCAAGCAfate and differentiation. In some other studies, DNA
methylation has been demonstrated to be required for
vertebrate early embryogenesis [19-21]. Here we collect
eight pairs of amniotic fluid and maternal blood samples
for selecting the hypermethylation and hypomethylation
DNA markers. The fetus and mother DNA samples are
all amplified by using the PowerPlex® 16 system kit in a
multiplex amplification reaction system and there is no
maternal DNA in fetus amniotic fluid.
DNA methylation analysis of the 8 pairs amniotic fluid
and maternal blood DNA samples are conducted by
using GeneChip® Human Tiling 2.0R Array set. In this
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of methylation markers respectively. In order to get fetus
methylation markers which are significant different from
that of mother in DNA methylation level, we have com-
pared the values of the DNA methylation levels of the
methylation markers of fetus with that of mother by
using MAT calculation (p < 0.0001). Scatter plots are
constructed to show the results of the comparison using
R Software Packages 3.0.1. Two of the Scatter plots were
showed in Figure 1. As shown in Figure 1, red solid tri-
angles which represent the DNA methylation level ofFigure 1 The scatter plots generated by using R software packages b
DNA marker (HOXA3) on chromosome 7; (B) The fetus hypomethylation D
the DNA methylation level of fetus in this chromosomal location; Blue ope
chromosomal location.fetus in this chromosomal location gathered together,
blue open circles which represent the DNA methylation
level of mother in this chromosomal location gathered
together, and red solid triangle groups are separated
from blue open circle groups. If the Scatter plots results
are the same as Figure 1, we can determine that there
must be significant different in DNA methylation level
from that of fetus and mother. According to the above
principle we select 59 fetus hypermethylation DNA
markers and 56 fetus hypomethylation DNA markers
which all show significant differences between fetus andased on the methylation degree. (A) The fetus hypermethylation
NA marker (FFAR2) on chromosome 19. *Red solid triangle represent
n circle represent the DNA methylation level of mother in this
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and function of the 59 fetus hypermethylation DNA
markers and 56 fetus hypomethylation DNA markers,
we check their associated genes where these markers lo-
cate in (http://www.ncbi.nlm.nih.gov/). We have finally
identified 9 fetus hypermethylation DNA markers and
12 fetus hypomethylation DNA markers and their asso-
ciated genes according to their function (showed in
Table 4).
To test and verify the 21 selected methylation DNA
markers by microarray analysis method in a whole-
genome wide, we used clone sequencing strategy. One of
the clone sequencing results was shown in Figure 2. The
results of clone sequencing were analyzed by Quantifica-
tion tool for Methylation Analysis (QUMA) and com-
pared by statistical software SPSS Version 13.0 using
Analysis of Variance (ANOVA) method (p < 0.01). Ac-
cording to the results of ANOVA, we finally selected 7
methylation DNA markers from the 21 according to
the results of the clone sequencing. They are FH4
(Chr21:38,791,600-38,792,000), FH7 (Chr9:129,579,800-
129,580,000), FL1 (Chr7:27,130,100-27,130,600), FL2 (Chr11:
62,127,350-62,127,700), FL3 (Chr3:32,835,500-32,835,800),
FL4 (Chr7:27,185,300-27,185,650) and FL7 (Chr7:27,148,050-
27,148,400).Table 4 The information of the 9 fetus hypermethylation DNA m
Marker ID Chromosomal locition Associa
FH1 ChrM:1-542 Mitocho
FH2 ChrM:16,025-16,571 Mitocho




FH7 Chr9:129,579,800-129,580,000 SH2 dom





FL4 Chr7:27,185,300-27,185,650 Homo s
FL5 Chr6:10,664,250-10,664,600 Homo s
FL6 Chr7:27,113,100-27,113,300 Homo s
FL7 Chr7:27,148,050-27,148,400 Homeob
FL8 Chr19:12,997,300-12,997,450 Nuclear
FL9 Chr8:116,753,900-116,754,200 Homo s
FL10 Chr5:95,321,600-95,321,800 Elongati
FL11 Chr7:32,213,400-32,213,600 Phospho
FL12 Chr8:82,066,300-82,066,500 PhosphoIf these 7 genes are really regulated by specific methy-
lation status in the fetus, the mRNA expression of ERG
and SH2D3C should be lower in the amniotic fluid,
whereas those of EML3, TRIM71, HOXA3, HOXA5,
and HOXA11 are higher in the amniotic fluid than in
the maternal peripheral blood cells. To verify the func-
tion of the 7 genes, we did the real-time quantitative
PCR (RTQ-PCR) comparison between amniotic fluid
samples and maternal peripheral blood cells on these 7
genes. The results of the RTQ-PCR were consistent with
the clone sequencing results. However, Analysis of Vari-
ance (ANOVA) showed that only SH2D3C was reduced
by 0.47 ± 0.33 folds (p < 0.01) in the amniotic fluid, and
EML3, TRIM71, HOXA3, and HOXA5 were enhanced
by 1.31 ± 0.72, 2.57 ± 1.37, 13.07 ± 9.45 and 2.38 ± 2.69
folds (p < 0.01) respectively in the amniotic fluid than in
the maternal peripheral blood cells. In order to clarify
whether the differences between mother and fetus were
due to fetus gender differences, the experimental data
were grouped according to fetus gender. The Analysis of
Variance (ANOVA) results showed that there were no
significant differences between male and female fetuses
in methylation status. So we conclude that the differ-
ences in methylation status between mother and fetus




y acid receptor 2 (FFAR2)
lastosis virus E26 oncogene onmcogene homolog (ERG)
drate (chondroitin 4) Sulfotransferase 12 (CHST12)
diate filament family orphan 1 (IFFO1)
ain containing 3C (SH2D3C)
ssociated protein 16-1 (KRTAP16-1)
patibility (minor) HA-1 (HMHA1)
ox A3 (HOXA3)
erm microtubule associated protein like 3 (EML3)
motif containing 71, E3 ubiquitin protein ligase (TRIM71)
apiens homeobox A11 (HOXA11)
apiens glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (GCNT2)
apiens homeobox A2 (HOXA2)
ox A5 (HOXA5)
factor I/X (NFIX) (CCAAT-binding transcription factor)
apiens trichorhinophalangeal syndrome I (TRPS1)
on factor, RNA polymerase II, 2 (ELL2)
diesterase 1C, calmodulin-dependent (PDE1C)
protein associated with glycosphingolipid microdomains 1 (PAG1)
Figure 2 The clone sequencing result of methylation DNA marker located on chromosome 21:38791600–38792000. The DNA Marker is a
fetus hypermethylation DNA marker and related with Erythroblastosis virus E26 oncogene onmcogene homolog (ERG) gene. (A) The clone
sequencing result of the mother, (B) The clone sequencing result of the fetus *X axis represents different methylation sites; Y axis represents
different clones. *black circle represent methylation sites; white circle represent unmethylated sites.
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encoded an adaptor protein and was a member of cyto-
plasmic protein family involved in cell migration. Until
now, Research on the function of SH2D3C gene was still
very rare. Marker FL2 was associated with EML3 gene
which was a nuclear microtubule-binding protein re-
quired for the correct alignment of chromosomes in
metaphase [22]. Marker FL3 was associated with
TRIM71 gene which cooperated with microRNAs to re-
press Cdkn1a expression and promote embryonic stem
cell proliferation [23,24]. HOX genes called homeobox
genes encoded the class of transcription factors were
found in clusters A, B, C, and D on four separate chro-
mosomes. The expression of these genes was spatially
and temporally regulated during embryonic develop-
ment. Marker FL1 was associated with HOXA3 gene
which was a member of HOX gene family and was part
of the A cluster on chromosome 7. It encoded a DNA-
binding transcription factor which may regulate gene ex-
pression, morphogenesis and differentiation. Marker FL7
was associated with HOXA5 gene which also encoded
the class of transcription factors. As HOXA3, the ex-
pression of this gene was spatially and temporally regu-
lated during embryonic development. Methylation of
this gene may result in the loss of its expression. Since
the encoded protein up-regulates the tumor suppressor
p53, this protein may play an important role in tumori-
genesis. The previous studies showed HOX genes were
involved in stem cell differentiation [25]. High-density
association study of the HOX gene for volumetric BMDat the femoral neck and lumbar spine among older men
was conducted and proved that HOXA gene regions
were associated with both femoral neck and lumbar
spine BMD [26]. However, HOX genes has not been
given enough attention that they can regulate gene ex-
pression, morphogenesis, and differentiation and were
involved in the regulation of uterine development and
required for female fertility.
Conclusions
In this study, we found 1 fetus hypermethylation DNA
markers and 4 fetus hypomethylation DNA markers
which all associated with the critical genes for fetus
growth and development. Our results may provide valu-
able information for future research of fetus growth and
development, and even can give some inspiration of the
studies of the pathological pregnancy, such as Unex-
plained Recurrent Spontaneous Abortion (URSA) and
early pregnant failure which generally occur at about
20 weeks in the embryonic development [27].
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